Alnylam Presents Primate Data on Complement-mediated Diseases Drug | GenomeWeb

Alnylam Pharmaceuticals this week released new preclinical data showing that its preclinical complement-mediated diseases drug ALN-CC5 could cut serum levels of its target protein by up to 98 percent in non-human primates.

The company also said that it expects to nominate a development candidate from the program in early 2014, with an investigational new drug application ready for filing in early 2015.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.